 |
|
Associations of Mortality With Ocular Disorders and an Intervention of High-Dose Antioxidants and Zinc in the Age-Related Eye Disease Study
AREDS Report No. 13
AREDS Research Group
Arch Ophthalmol. 2004;122:716-726.
Objective To assess the association of ocular disorders and high doses of antioxidants or zinc with mortality in the Age-Related Eye Disease Study (AREDS).
Methods Baseline fundus and lens photographs were used to grade the macular and lens status of AREDS participants. Participants were randomly assigned to receive oral supplements of high-dose antioxidants, zinc, antioxidants plus zinc, or placebo. Risk of all-cause and cause-specific mortality was assessed using adjusted Cox proportional hazards models.
Results During median follow-up of 6.5 years, 534 (11%) of 4753 AREDS participants died. In fully adjusted models, participants with advanced age-related macular degeneration (AMD) compared with participants with few, if any, drusen had increased mortality (relative risk [RR], 1.41; 95% confidence interval [CI], 1.08-1.86). Advanced AMD was associated with cardiovascular deaths. Compared with participants having good acuity in both eyes, those with visual acuity worse than 20/40 in 1 eye had increased mortality (RR, 1.36; 95% CI, 1.12-1.65). Nuclear opacity (RR, 1.40; 95% CI, 1.12-1.75) and cataract surgery (RR, 1.55; 95% CI, 1.18-2.05) were associated with increased all-cause mortality and with cancer deaths. Participants randomly assigned to receive zinc had lower mortality than those not taking zinc (RR, 0.73; 95% CI, 0.61-0.89).
Conclusions The decreased survival of AREDS participants with AMD and cataract suggests that these conditions may reflect systemic rather than only local processes. The improved survival in individuals randomly assigned to receive zinc requires further study.
The Writing Team for the AREDS Research Group is Traci E. Clemons, PhD; Natalie Kurinij, PhD; Robert D. Sperduto, MD; and Susan B. Bressler, MD. Other members of the AREDS Research Group are listed in a box above. The Writing Team members and the AREDS investigators have no relevant financial interest in this article.
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Serum zinc and pneumonia in nursing home elderly
Meydani et al.
Am. J. Clin. Nutr. 2007;86:1167-1173.
ABSTRACT
| FULL TEXT
Age-Related Macular Degeneration and Cancer Mortality in the Atherosclerosis Risk in Communities Study
Cheung et al.
Arch Ophthalmol 2007;125:1241-1247.
ABSTRACT
| FULL TEXT
Visual Impairment, Age-Related Macular Degeneration, Cataract, and Long-term Mortality: The Blue Mountains Eye Study
Cugati et al.
Arch Ophthalmol 2007;125:917-924.
ABSTRACT
| FULL TEXT
Circulating Inflammatory Markers and Hemostatic Factors in Age-Related Maculopathy: A Population-Based Case-Control Study
Wu et al.
IOVS 2007;48:1983-1988.
ABSTRACT
| FULL TEXT
Zinc: Mechanisms of Host Defense
Prasad
J. Nutr. 2007;137:1345-1349.
ABSTRACT
| FULL TEXT
Zinc supplementation decreases incidence of infections in the elderly: effect of zinc on generation of cytokines and oxidative stress
Prasad et al.
Am. J. Clin. Nutr. 2007;85:837-844.
ABSTRACT
| FULL TEXT
Heart Outcomes Prevention Evaluation-The Ongoing Outcomes Study, Vitamin E, and Age-Related Macular Degeneration--Reply
Chew and Clemons
Arch Ophthalmol 2006;124:1665-1666.
FULL TEXT
Age-related eye disease, visual impairment, and survival: the beaver dam eye study.
Knudtson et al.
Arch Ophthalmol 2006;124:243-249.
ABSTRACT
| FULL TEXT
Prevalence of Age-Related Macular Degeneration in a Population-Based Sample of Hispanic People in Arizona: Proyecto VER
Munoz et al.
Arch Ophthalmol 2005;123:1575-1580.
ABSTRACT
| FULL TEXT
The relation between C reactive protein and age related macular degeneration in the Cardiovascular Health Study
McGwin et al.
Br. J. Ophthalmol. 2005;89:1166-1170.
ABSTRACT
| FULL TEXT
Vitamin E and the Age-Related Eye Disease Study Supplementation for Age-Related Macular Degeneration
Chew and Clemons
Arch Ophthalmol 2005;123:395-396.
FULL TEXT
From the Library
Br. J. Ophthalmol. 2004;88:1104-1104.
FULL TEXT
|
